A bacterial regulator shaping drug resistance and survival

Tuberculosis remains a major global health threat, made worse by the rise of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). New drugs and smarter treatment strategies are urgently needed to overcome resistance and save lives. Recent work has flagged a specific change in a gene called cwlM (Rv3915) — an M237V substitution — that was linked to increased susceptibility to the common antibiotic amoxicillin. To dig into how cwlM affects drug sensitivity and the bacterium’s ability to live inside host cells, researchers led by Maria João Catalão used a widely accepted laboratory stand-in for Mtb, Mycobacterium smegmatis (Msm). They engineered a cwlM knockdown strain in Msm using CRISPR interference (CRISPRi), aiming to reduce cwlM activity and observe the consequences. The goal was to test whether altering this single gene would change how the bacteria respond to beta-lactam antibiotics and whether it would affect survival inside human-like immune cells. This approach lets scientists probe gene function in a safer, faster model while keeping a focus on traits relevant to Mtb infection and drug resistance.

The team confirmed that the CRISPRi system successfully reduced cwlM expression using Quantitative RT-PCR. Follow-up phenotyping showed that processes tied to CwlM are essential for normal mycobacterial viability, meaning the bacteria struggled when cwlM was repressed. Antibiotic susceptibility assays indicated that CwlM SMEG may promote resistance to certain beta-lactams, with the biggest effects seen against meropenem and cefotaxime, and earlier observations had connected an M237V substitution in cwlM with increased susceptibility to amoxicillin. The researchers also tested how the knockdown strains fared inside immune cells and found that CwlM SMEG supports intracellular survival within THP-1-derived macrophages. To clarify how CwlM works, they purified recombinant CwlM TB and ran a Micrococcus luteus-derived PG-based zymogram to test for peptidoglycan activity. That assay showed CwlM TB lacks detectable PG-hydrolytic activity, pointing away from a direct enzyme role and toward a regulatory role in peptidoglycan (PG) biosynthesis instead.

Together, these findings indicate that CwlM plays a dual role: it helps mycobacteria resist certain beta-lactam antibiotics and it supports survival inside host-like immune cells, even though it does not appear to cut peptidoglycan itself. Because CwlM-related processes are essential for bacterial viability and the protein appears highly vulnerable to perturbation, the work highlights cwlM as a candidate therapeutic target. If further studies confirm similar effects in Mycobacterium tuberculosis clinical strains, drugs that block CwlM function could sensitize bacteria to beta-lactams such as amoxicillin, meropenem and cefotaxime or weaken their ability to persist inside macrophages. The absence of detectable PG-hydrolytic activity in CwlM TB shifts the focus toward its regulatory interactions in PG biosynthesis, which may open new avenues for drug design that do not rely on traditional enzyme inhibition. Overall, the study supports deeper investigation of CwlM and related pathways as part of efforts to counter MDR tuberculosis.